{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:52:24Z","timestamp":1789206744617,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Japanese encephalitis virus (JEV) has a significant impact on public health. An estimated three billion people in 'at-risk\u2019 regions remain unvaccinated and the number of unvaccinated individuals in certain Asian countries is increasing. Consequently, there is an urgent need for the development of novel therapeutic agents against Japanese encephalitis. Nitazoxanide (NTZ) is a thiazolide anti-infective licensed for the treatment of parasitic gastroenteritis. Recently, NTZ has been demonstrated to have antiviral properties. In this study, the anti-JEV activity of NTZ was evaluated in cultured cells and in a mouse model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>JEV-infected cells were treated with NTZ at different concentrations. The replication of JEV in the mock- and NTZ-treated cells was examined by virus titration. NTZ was administered at different time points of JEV infection to determine the stage at which NTZ affected JEV replication. Mice were infected with a lethal dose of JEV and intragastrically administered with NTZ from 1 day post-infection. The protective effect of NTZ on the JEV-infected mice was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      NTZ significantly inhibited the replication of JEV in cultured cells in a dose dependent manner with 50% effective concentration value of 0.12\u2009\u00b1\u20090.04\u00a0\u03bcg\/ml, a non-toxic concentration in cultured cells (50% cytotoxic concentration\u2009=\u200918.59\u2009\u00b1\u20090.31\u00a0\u03bcg\/ml). The chemotherapeutic index calculated was 154.92. The viral yields of the NTZ-treated cells were significantly reduced at 12, 24, 36 and 48\u00a0h post-infection compared with the mock-treated cells. NTZ was found to exert its anti-JEV effect at the early-mid stage of viral infection. The anti-JEV effect of NTZ was also demonstrated\n                      <jats:italic>in vivo<\/jats:italic>\n                      , where 90% of mice that were treated by daily intragastric administration of 100\u00a0mg\/kg\/day of NTZ were protected from a lethal challenge dose of JEV.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Both\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      data indicated that NTZ has anti-JEV activity, suggesting the potential application of NTZ in the treatment of Japanese encephalitis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1743-422x-11-10","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T05:26:20Z","timestamp":1390454780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model"],"prefix":"10.1186","volume":"11","author":[{"given":"Zixue","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiqun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,23]]},"reference":[{"key":"2368_CR1","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1086\/428839","volume":"40","author":"LM Fox","year":"2005","unstructured":"Fox LM, Saravolatz LD: Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005, 40: 1173-1180. 10.1086\/428839","journal-title":"Clin Infect Dis"},{"key":"2368_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/322038","volume":"184","author":"JF Rossignol","year":"2001","unstructured":"Rossignol JF, Ayoub A, Ayers MS: Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001, 184: 381-384. 10.1086\/322038","journal-title":"J Infect Dis"},{"key":"2368_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cgh.2005.12.020","volume":"4","author":"JF Rossignol","year":"2006","unstructured":"Rossignol JF, Kabil SM, el-Gohary Y, Younis AM: Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. Clin Gastroenterol Hepatol 2006, 4: 320-324. 10.1016\/j.cgh.2005.12.020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2368_CR4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.4269\/ajtmh.1997.56.637","volume":"56","author":"O Doumbo","year":"1997","unstructured":"Doumbo O, Rossignol JF, Pichard E, Traore HA, Dembele TM, Diakite M, Traore F, Diallo DA: Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am J Trop Med Hyg 1997, 56: 637-639.","journal-title":"Am J Trop Med Hyg"},{"key":"2368_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(06)68852-1","volume":"368","author":"JF Rossignol","year":"2006","unstructured":"Rossignol JF, Abu-Zekry M, Hussein A, Santoro MG: Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 2006, 368: 124-129. 10.1016\/S0140-6736(06)68852-1","journal-title":"Lancet"},{"key":"2368_CR6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/j.1365-2036.2006.03128.x","volume":"24","author":"JF Rossignol","year":"2006","unstructured":"Rossignol JF, El-Gohary YM: Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther 2006, 24: 1423-1430. 10.1111\/j.1365-2036.2006.03128.x","journal-title":"Aliment Pharmacol Ther"},{"key":"2368_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.antiviral.2007.08.005","volume":"77","author":"BE Korba","year":"2008","unstructured":"Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF: Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008, 77: 56-63. 10.1016\/j.antiviral.2007.08.005","journal-title":"Antiviral Res"},{"key":"2368_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2217\/17460913.3.5.539","volume":"3","author":"JF Rossignol","year":"2008","unstructured":"Rossignol JF, Keeffe EB: Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. Future Microbiol 2008, 3: 539-545. 10.2217\/17460913.3.5.539","journal-title":"Future Microbiol"},{"key":"2368_CR9","doi-asserted-by":"publisher","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","volume":"284","author":"JF Rossignol","year":"2009","unstructured":"Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG: Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009, 284: 29798-29808. 10.1074\/jbc.M109.029470","journal-title":"J Biol Chem"},{"key":"2368_CR10","doi-asserted-by":"publisher","first-page":"891010","DOI":"10.4061\/2010\/891010","volume":"2010","author":"LV Ashton","year":"2010","unstructured":"Ashton LV, Callan RL, Rao S, Landolt GA: In vitro susceptibility of canine influenza A (H3N8) virus to nitazoxanide and tizoxanide. Vet Med Int 2010, 2010: 891010.","journal-title":"Vet Med Int"},{"key":"2368_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1517\/17425250902988487","volume":"5","author":"JF Rossignol","year":"2009","unstructured":"Rossignol JF: Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol 2009, 5: 667-674. 10.1517\/17425250902988487","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2368_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1053\/j.gastro.2008.11.037","volume":"136","author":"JF Rossignol","year":"2009","unstructured":"Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB: Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009, 136: 856-862. 10.1053\/j.gastro.2008.11.037","journal-title":"Gastroenterology"},{"key":"2368_CR13","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1128\/AAC.01159-06","volume":"51","author":"PS Hoffman","year":"2007","unstructured":"Hoffman PS, Sisson G, Croxen MA, Welch K, Harman WD, Cremades N, Morash MG: Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob Agents Chemother 2007, 51: 868-876. 10.1128\/AAC.01159-06","journal-title":"Antimicrob Agents Chemother"},{"key":"2368_CR14","first-page":"1151A","volume":"48","author":"M Elazar","year":"2008","unstructured":"Elazar M, Liu M, McKenna S, Liu P, Gehrig EA, Elfert A, Puglisi J, Rossignol JF, Glenn JS: Nitazoxanide (NTZ) is an inducer of eIF2a and PKR phosphorylation [abstract]. Hepatology 2008, 48: 1151A.","journal-title":"Hepatology"},{"key":"2368_CR15","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1371\/journal.pntd.0000437","volume":"3","author":"D Ghosh","year":"2009","unstructured":"Ghosh D, Basu A: Japanese encephalitis-a pathological and clinical perspective. PLoS Negl Trop Dis 2009, 3: e437. 10.1371\/journal.pntd.0000437","journal-title":"PLoS Negl Trop Dis"},{"key":"2368_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/rmv.1710","volume":"22","author":"Y Zheng","year":"2012","unstructured":"Zheng Y, Li M, Wang H, Liang G: Japanese encephalitis and Japanese encephalitis virus in mainland China. Rev Med Virol 2012, 22: 301-322. 10.1002\/rmv.1710","journal-title":"Rev Med Virol"},{"key":"2368_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3201\/eid1501.080311","volume":"15","author":"TE Erlanger","year":"2009","unstructured":"Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K: Past, present, and future of Japanese encephalitis. Emerg Infect Dis 2009, 15: 1-7. 10.3201\/eid1501.080311","journal-title":"Emerg Infect Dis"},{"key":"2368_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jcv.2010.06.009","volume":"49","author":"N Gupta","year":"2010","unstructured":"Gupta N, Lomash V, Rao PV: Expression profile of Japanese encephalitis virus induced neuroinflammation and its implication in disease severity. J Clin Virol 2010, 49: 4-10. 10.1016\/j.jcv.2010.06.009","journal-title":"J Clin Virol"},{"key":"2368_CR19","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/jac\/dkq074","volume":"65","author":"M Anantpadma","year":"2010","unstructured":"Anantpadma M, Stein DA, Vrati S: Inhibition of Japanese encephalitis virus replication in cultured cells and mice by a peptide-conjugated morpholino oligomer. J Antimicrob Chemother 2010, 65: 953-961. 10.1093\/jac\/dkq074","journal-title":"J Antimicrob Chemother"},{"key":"2368_CR20","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1371\/journal.pmed.0030096","volume":"3","author":"P Kumar","year":"2006","unstructured":"Kumar P, Lee SK, Shankar P, Manjunath N: A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med 2006, 3: e96. 10.1371\/journal.pmed.0030096","journal-title":"PLoS Med"},{"key":"2368_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.virusres.2007.11.014","volume":"132","author":"WB Qi","year":"2008","unstructured":"Qi WB, Hua RH, Yan LP, Tong GZ, Zhang GH, Ren T, Wu DL, Liao M: Effective inhibition of Japanese encephalitis virus replication by small interfering RNAs targeting the NS5 gene. Virus Res 2008, 132: 145-151. 10.1016\/j.virusres.2007.11.014","journal-title":"Virus Res"},{"key":"2368_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/jac\/dkm503","volume":"61","author":"V Swarup","year":"2008","unstructured":"Swarup V, Ghosh J, Mishra MK, Basu A: Novel strategy for treatment of Japanese encephalitis using arctigenin, a plant lignan. J Antimicrob Chemother 2008, 61: 679-688. 10.1093\/jac\/dkm503","journal-title":"J Antimicrob Chemother"},{"key":"2368_CR23","first-page":"925830","volume":"2012","author":"SJ Chang","year":"2012","unstructured":"Chang SJ, Chang YC, Lu KZ, Tsou YY, Lin CW: Antiviral activity of isatis indigotica extract and its derived indirubin against Japanese encephalitis virus. Evid Based Complement Alternat Med 2012, 2012: 925830.","journal-title":"Evid Based Complement Alternat Med"},{"key":"2368_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/1743-422X-8-209","volume":"8","author":"X Deng","year":"2011","unstructured":"Deng X, Shi Z, Li S, Wang X, Qiu Y, Shao D, Wei J, Tong G, Ma Z: Characterization of nonstructural protein 3 of a neurovirulent Japanese encephalitis virus strain isolated from a pig. Virol J 2011, 8: 209. 10.1186\/1743-422X-8-209","journal-title":"Virol J"},{"key":"2368_CR25","first-page":"661","volume-title":"Statistical method in biological assay. 1st edition","author":"DJ Finney","year":"1952","unstructured":"Finney DJ: Statistical method in biological assay. 1st edition. Edited by: Finney DJ. London: Griffin; 1952:661."},{"key":"2368_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5099\/aj100100043","volume":"2","author":"N Anand","year":"2010","unstructured":"Anand N, Kumar S, Gowal D: Standardization of plaque assay of Japanese encephalitis virus (Nakayama NIH strain) on BHK-21 (Cl-13) cell line. Am J Biomed Sci 2010, 2: 43-50.","journal-title":"Am J Biomed Sci"},{"key":"2368_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bbrc.2008.09.117","volume":"377","author":"Y Qiu","year":"2008","unstructured":"Qiu Y, Shen Y, Li X, Liu Q, Ma Z: Polyclonal antibody to porcine p53 protein: a new tool for studying the p53 pathway in a porcine model. Biochem Biophys Res Commun 2008, 377: 151-155. 10.1016\/j.bbrc.2008.09.117","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-11-10.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:59:28Z","timestamp":1630537168000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-11-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,23]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2368"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-11-10","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,23]]},"assertion":[{"value":"10 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"10"}}